FDG-PET/CT foretells melanoma therapy response

FDG-PET/CT scans performed during early treatment for melanoma could help clinicians...Read more on AuntMinnie.comRelated Reading: JNM: Radiolabeled benzamides could aid melanoma patients ARRS: CT plus serum data predict survival in melanoma patients
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

CONCLUSION: The controlled synthesis, sensitive PET imaging, and optimal tumor targeting suggested the potential of targeted AuNCs for melanoma theranostics. PMID: 29873290 [PubMed - in process]
Source: Molecular Imaging - Category: Radiology Tags: Mol Imaging Source Type: research
CONCLUSIONS: Six-monthly CT-scan of the chest, abdomen and pelvis is a cost-effective technique for the early detection of metastases in the first four years of follow-up in melanoma patients with AJCC stages IIC and III, and during the first three years in stage AJCC IIB patients. In addition, brain-MRI has been shown to be a cost-effective technique only during the first year of follow-up in patients with melanoma AJCC stage IIC and III. This article is protected by copyright. All rights reserved. PMID: 29876940 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
ConclusionQuantitative analysis of18F-FDG PET data does not provide additional information in treatment response evaluation of metastatic melanoma patients receiving ipilimumab. PERCIMT criteria correlated better with clinical response.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Conclusions: Incidental findings are often not dictated in reports. In some instances, the incidental genitourinary findings changed the course of therapy. For example, focal uptake noted on the foreskin was determined to be squamous cell carcinoma. Focal uptake in the vagina was determined to be melanoma. This exhibit will identify findings that should be reported to ensure adequate treatment.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Educational Exhibits Source Type: research
Conclusions: Preliminary data from this ongoing study shows that 89Zr-Df-IAB22M2C imaging is safe, has favorable biodistribution and kinetics with possible detection of lesions at 24 - 48 h p.i. More patients are being studied using higher Mb mass. Research Support: Research Support: ImaginAb, Inc.; Parker Institute for Cancer Immunotherapy
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Other Solid Tumors Source Type: research
Conclusion: With the addition of multiple N-methylations, CCZ01099 retained good binding affinity to MC1R, with improved selectivity to MC1R, and greatly enhanced in vivo stability. PET imaging and biodistribution with 68Ga-CCZ01099 exhibited clear melanoma visualization and good tumor-to-background contrast.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Preclinical Probes for Oncology III Source Type: research
Conclusions:In a preclinical syngeneic murine melanoma model, we demonstrate a cooperative therapeutic effect with combined TRT and CB. This confirms that systemic administration of 90Y-NM600 can deliver an immunomodulatory radiation dose to the tumor microenvironment without inducing systemic immunosuppression. We are now testing this approach in similar preclinical studies in combination with other immunotherapies and in the setting of disseminated metastatic disease.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Center for Therapy Excellence YIA Symposium Source Type: research
Conclusions: Cardiac angiosarcoma had high FDG uptake, which may be due to its poor differentiation and biological behaviors of the tumor cells. The FDG PET/CT scan can detect the primary tumor extension, metastases at diagnosis, postsur­gical residue and/or relapse and metastases. But successful diagnosis in this rare case relied on the comprehensive utilization of multimodality imaging techniques.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Sarcoma/ Melanoma Source Type: research
Conclusion: Markedly increased 18F-FDG uptake on interim response PET/CT scans in patients treated with pembrolizumab appears to identify nonresponding patients. Figure 1. 18F-FDG positron emission tomography/computed tomography (PET/CT) showing progression and response in patients with advanced melanoma treated with the immune checkpoint inhibitor pembrolizumab. Maximum intensity projection (MIP) images of an 88 year-old patient with metastatic melanoma to the liver before initiation of therapy (1a) and after 3 cycles of treatment (1b) show progressive disease on the scan. This patient ultimately progressed on therapy (n...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Sarcoma/ Melanoma Source Type: research
Conclusions: Our study suggests that the biodistribution and effective radiation dose of 18F-P3BZA are safe and compatible for clinical use. We also investigated the first-in-human clinical application of 18F-P3BZA which showed favorable delineated melanoma lesions in patients, demonstrating the great potential of 18F-P3BZA for diagnostic PET imaging of melanoma.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Dosimetry Posters Source Type: research
More News: CT Scan | Melanoma | PET Scan | Radiology | Skin Cancer